Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

被引：106
作者：
Belvederi Murri M. [1 ,2 ]
Guaglianone A. [1 ]
Bugliani M. [1 ]
Calcagno P. [1 ]
Respino M. [1 ]
Serafini G. [1 ]
Innamorati M. [3 ]
Pompili M. [3 ]
Amore M. [1 ]
机构：
[1] Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Largo Rosanna Benzi, 10, Genoa
[2] Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London
[3] Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome
来源：
Drugs in R&D | 2015年 / 15卷 / 1期
关键词：
Clozapine; Risperidone; Olanzapine; Quetiapine; Aripiprazole;
D O I：
10.1007/s40268-014-0078-0
中图分类号：
学科分类号：
摘要：
Background: Neuroleptic malignant syndrome (NMS) is a rare, severe, idiosyncratic adverse reaction to antipsychotics. Second-generation antipsychotics (SGAs) were originally assumed to be free from the risk of causing NMS, however several cases of NMS induced by SGAs (SGA-NMS) have been reported.Objectives: The aim of this study was to systematically review available studies and case reports on SGA-NMS and compare the presentation of NMS induced by different SGAs.Data Sources: Citations were retrieved from PubMed up to November 2013, and from reference lists of relevant citations.Study Eligibility Criteria: Eligibility criteria included (a) primary studies reporting data on NMS, with at least 50 % of the sample receiving SGAs; or (b) case reports and case reviews reporting on NMS induced by SGA monotherapy, excluding those due to antipsychotic withdrawal.Study Appraisal and Synthesis Methods: A standardized method for data extraction and coding was developed for the analysis of eligible case reports.Results: Six primary studies and 186 individual cases of NMS induced by SGAs were included. Primary studies suggest that SGA-NMS is characterized by lower incidence, lower clinical severity, and less frequent lethal outcome than NMS induced by first-generation antipsychotics. Systematic analysis of case reports suggests that even the most recently marketed antipsychotics are not free from the risk of inducing NMS. Furthermore, clozapine-, aripiprazole- and amisulpride-induced NMS can present with atypical features more frequently than other SGA-NMS, i.e. displaying less intense extrapyramidal symptoms or high fever.Limitations: Case reports report non-systematic data, therefore analyses may be subject to bias.Conclusions and Implications of Key Findings: Clinicians should be aware that NMS is virtually associated with all antipsychotics, including those most recently marketed. Although apparently less severe than NMS induced by older antipsychotics, SGA-NMS still represent a relevant clinical issue. © 2015, The Author(s).
引用
收藏
页码：45 / 62
页数：17
相关论文
共 97 条
[61]  
Natesan S., Reckless G.E., Barlow K.B., Et al., Amisulpride the ‘atypical’ atypical antipsychotic: comparison to haloperidol, risperidone and clozapine, Schizophr Res, 105, pp. 224-235, (2008)
[62]  
de Leon J., Wynn G., Sandson N.B., The pharmacokinetics of paliperidone versus risperidone, Psychosomatics, 51, pp. 80-88, (2010)
[63]  
Duggal H.S., Possible neuroleptic malignant syndrome associated with paliperidone, J Neuropsychiatry Clin Neurosci, 19, pp. 477-478, (2007)
[64]  
Mantas C., Kalabokis G., Goulia P., Et al., Possible neuroleptic malignant syndrome during paliperidone administration: a case report, J Clin Psychopharmacol, 30, pp. 89-91, (2010)
[65]  
Han C., Lee S.J., Pae C.U., Paliperidone-associated atypical neuroleptic malignant syndrome: a case report, Prog Neuropsychopharmacol Biol Psychiatry, 35, pp. 650-651, (2011)
[66]  
Nayak R.B., Bhogale G.S., Patil N.M., Et al., Paliperidone-induced neuroleptic malignant syndrome, J Neuropsychiatry Clin Neurosci, 23, pp. 14-15, (2011)
[67]  
Borovicka M.C., Bond L.C., Gaughan K.M., Ziprasidone- and lithium-induced neuroleptic malignant syndrome, Ann Pharmacother, 40, pp. 139-142, (2006)
[68]  
Gray N.S., Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson’s disease: a diagnostic challenge, Hum Psychopharmacol, 19, pp. 205-207, (2004)
[69]  
Leibold J., Patel V., Hasan R.A., Neuroleptic malignant syndrome associated with ziprasidone in an adolescent, Clin Ther, 26, pp. 1105-1108, (2004)
[70]  
Lewis A.L., Pelic C., Kahn D.A., Malignant catatonia in a patient with bipolar disorder, B12 deficiency, and neuroleptic malignant syndrome: one cause or three?, J Psychiatr Pract, 15, pp. 415-422, (2009)
12345678910